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Introduction
Since the International Agency for Research on Cancer (IARC) classified Human papillomavirus (HPV) 16 as 'oncogenic' to a number of cancer sites [1] our understanding of the molecular, clinical and epidemiological aspects of oropharyngeal squamous cell carcinoma (OPSCC) has dramatically improved. At the same time, the global burden of the disease has steadily increased and it has been predicted to surpass cervical cancer in some developed countries [2] . An examination of accumulated knowledge regarding the HPV-related OPSCC disease thus far is warranted.
Human papillomavirus
HPVs are small viruses containing a circular double-stranded DNA genome of $8 kb organised into three major regions: (i) an upstream regulatory region (URR) that is the origin of replication and includes transcription factor-binding sites and controls gene expression; (ii) an early region, encoding for six genes involved in multiple functions including viral replication and cell transformation (E1, E2, E4, E5, E6, E7), and (iii) a late region, encoding for the L1 and L2 capsid proteins which self-assemble to yield the virion [3] . The main functions of each gene are summarised in Figure 1 .
To date, more than 200 HPV genotypes have been identified [3] . Mucosal HPV types have been categorised into 'high-risk' (HR) and 'low-risk' (LR) types according to their potential to induce malignancy in the cervix. Twelve HR-HPV types are classified as oncogenic by IARC (group 1: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59) [4] . Among the HR-HPV types involved in head and neck carcinogenesis, HPV16 is by far the most common, with a prevalence over the 80% in OPSCC, followed by HPV18 (3%) [5] [6] [7] . Other genotypes have been also reported in a smaller number of patients such as HPV33, HPV35 and HPV58 [5, 6, 8] .
Global burden and incidence trends
In 2007, the IARC concluded that there was sufficient evidence for the carcinogenic role of HPV16 in tumours of the oropharynx [1] , and estimated that $31% of OPSCC cases were attributed to HPV [9] . This estimate, as well as previous metaanalyses assessing the quantitative contribution of HPV, found high geographic heterogeneity in HPV-attributable fractions (AFs) of OPSCC, ranging from <20% in Southern Europe to more than 60% in North America [5, 6, 10, 11] . Most of these estimations were based on HPV-DNA detection. However, HPV-DNA detection alone is not sufficient to classify an OPSCC as HPV-driven since the presence of HPV-DNA could merely reflect a transitory infection and not an HPV-driven oncogenic process [12] [13] [14] [15] .
A recent study developed by our group estimated HPV-AFs in different sites of HNSCC by quantifying the expression of a selection of biomarkers of HPV-induced carcinogenesis in 3680 patients from 29 countries [7] . The global range of HPV-AFs for OPSCC when considering two additional markers of viral biological activity (HPV-DNA plus E6*I mRNA and/or p16 INK4a ) was between 18.5% and 22.4%, substantially lower than that of 67.2% reported in North America [8] . With our regional estimates [7] and Jordan et al.'s study [8] in order to cover the US data, we were able to estimate the annual number of new incident OPSCC cases attributable to HPV worldwide, in 25 409 [16] , near to the number of new cases recently estimated by the IARC of 29 000 [9] . OPSCC includes tonsil and base of the tongue subsites, but also cancer of the walls of the oropharynx and soft palate; however, the presence of HPV is much higher in the tonsils and base of the tongue.
HPV-AFs for HNSCC, outside the oropharynx, are substantially lower. It is interesting to note that despite the HPV-AFs for oral cavity and larynx squamous cell carcinomas described in previous meta-analysis [5, 6] (23.5%-24.2% and 24.0%-22.1%, respectively), the prevalence is lower when evaluating robust single studies, finding a 5.9%-4.4% HPV-AFs for oral cavity and 3.5%-1.7% for larynx [7, 17] . These differences, may be due to misclassification of anatomic subsites, as HPV-AFs for subsites within the oral cavity or the larynx that were more proximal to the oropharynx were higher than those distant or to positive reporting bias [7] .
Risk factors for HPV-related OPSCC
Smoking and alcohol consumption are the classic and wellestablished risk factors for HNSCC, including OPSCC. Trends in smoking prevalence differ significantly across geographic regions, and a notable decrease from 1980 to 2012 has been observed in men and women in North America and Northern Europe [18] . In addition, sexual behaviour is now established as a risk factor for HPVrelated OPSCC, with lifetime number of oral sex partners as the factor most strongly associated with OPSCC. Furthermore, as for smoking, the prevalence of oral sex dramatically differs across populations [17] . Other risk factors include open mouth kissing, vaginal and any sex partners, aged 18 years at the time of first oral sex, marijuana use and history of cervical HPV infection [19] . Thus, differences in risk factor exposure and sexual behaviour could explain in part differences in AFs observed across regions and across decades. It is still unclear whether tobacco and/or alcohol use can act as co-factors and/or effect modifiers in the risk of developing HPV-related OPSCC. Recently, Anantharaman et al. reported after pooling two HNSCC studies with HPV16 serology data that smoking was consistently associated with increased risk of OPSCC regardless of HPV status [20] . This suggests that HPV16 and smoking are independent risk factors, as it has been reported previously [21] [22] [23] . Interestingly, new data have been reported concluding that the population-level burden of HPV-related OPSCC is significantly higher among ever-smokers than neversmokers in the USA, despite HPV-related OPSCC is characterised as a disease of never smokers due to high HPV prevalence in OPSCC among never-smokers [24] .
When compared with patients with non HPV-related OPSCC, patients with HPV-related OPSCC tend to be younger (aged <60 years) and to smoke and drink less; also a higher percentage of them are men (in most regions), and report more oral sex partners and a higher socioeconomic status [22, [25] [26] [27] . Age differences may be explained by differences in sexual practices in younger versus older cohorts. Regarding gender, a recent systematic review on differences in the proportion of HPV-AF in OPSCC between men and women revealed a geographic heterogeneous pattern, showing the highest men to women ratio in the USA (1.5) and the lowest in Asia and some European countries (0.7) [28] .
From infection to cancer: the natural history
Our current knowledge of the carcinogenic process from infection to cancer in OPSCC is still limited and mostly extrapolated from the cervical cancer model. The mucosal lining of the tonsil and tonsillar crypts allows direct passage of not only immune cells but also of pathogens such as HPV [29] . When HPV infection is not cleared, its persistence can lead to a precancerous lesion that if it does not regress will eventually progress to invasive OPSCC ( Figure 2 ). However, until now no oropharyngeal premalignant disorders have been well established. Persistent infections may progress to invasive cancer within 10 years [30] , nevertheless the majority of these infections, are cleared within a year or two [31] .
On the other hand, global prevalence of oral HPV infection in asymptomatic subjects is not yet well established. A meta-analysis of 4441 subjects showed that 4.5% had an oral HPV infection, and that the rates among men and women were similar [32] , whereas in a more recent original study carried out in the US region, prevalence of oral HPV infection was 6.9%, with a higher prevalence among men (10.1% versus 3.6%, P ¼ 0.001) [33] . Figure 2 . Natural history of Human Papilloma Virus oral infection and the carcinogenesis process. The oral mucosa is exposed to the HPV, when the infection persists and it is not cleared could lead to the development of a HPV-related precancerous lesion. If the precancerous lesion does not regress, it can progress into an invasive cancer. Different steps of preventive strategies are shown in the bottom of the figure, they will be discuss in 'Preventive strategies' section. HPV, human papilloma virus; OPSCC, oropharyngeal squamous cell carcinoma.
Molecular biology of HPV-related OPSCC
E6 and E7 early proteins have a main role in HPV-related OPSCC carcinogenesis ( Figure 3 ) [34] . E6 inhibits p53, while E7 binds to pRb, promotes its degradation and the release of the E2F transcription factor [3, 35] . This results in the de-regulation of the G1/S cell cycle check point and the activation of S-phase re-entry and viral replication. As a consequence of the E7 activation, p16 INK4a is overexpressed and released from the inhibitory activity of the pRb/E2F complex, allowing epithelial cells to escape from oncogene-induce senescence and to activated survival signalling pathways [36] . p16
INK4a overexpression is critical for cell survival in HPV-associated tumours, while it is frequently inactivated in HPV non-related tumours. This makes the p16 INK4a overexpression an acceptable surrogate marker of transcriptionally active HPV in oropharyngeal carcinogenesis [37] . However, p16
INK4a overexpression should be complemented with HPV DNA detection to reduce the risk of misclassification of HPVnegative tumours, which can sometimes maintain the p16 INK4a expression [38] . Chromosomal instability, which greatly increases the risk of accumulation of genomic alterations, the inhibition of the apoptotic signalling and an increase of the telomerase activity are associated directly with the E6/E7 expression or the inactivation of p53 and pRB tumour suppressor genes [34, 39] .
E5 is not necessarily expressed but when it is, it influences a variety of signalling pathways including the epidermal growth factor receptor (EGFR), the immune recognition and the apoptosis regulation [40] . Other early proteins (E1, E2 and E4) are essential to complete the viral cycle, but their activity is not crucial to promote the oncogenic transformation. The accumulation of additional genetic or epigenetic alterations and HPV integration are also important events for neoplastic transformation and tumour progression.
HPV integration
It is well recognized for cervical cancer that HPV integration into the host DNA allows greater expression of oncogenes E6/E7 and favours oncogenesis; but this process is not mandatory [41] . A whole-genome sequence study in HNSCC tumours revealed that HPV integration impacted on the host genome by amplification of oncogenes and disruption of tumour suppressor genes as well as driving inter/intrachromosomal rearrangements; Akagi et al. mapped HPV integration and proposed a model of 'looping' to explain this procedure [42] . Moreover, distinct gene expression profiles and DNA methylation patterns have been described in tumours that show or not show HPV integration into the cell genome [43] . Thus, HPV integration may play a role in genomic instability modifying the outcomes on HPV-related OPSCC. Nevertheless, two recent studies, reported that the majority of HPV-related OPSCC have either integrated or both episomal and integrated HPV with no significant differences in survival among groups [44, 45] ; however, based on advances in integration technological assessment, further studies must be carried out.
Landscape of somatic genomic alterations in HPVrelated OPSCC and potential therapeutic targets
The Cancer Genome Atlas reviewed 279 HNSCC samples: 36 (13%) were classified as HPV-related and 33 (12%) were from the oropharynx [46] . Different alterations in HPV-related OPSCC were described: loss of TNF receptor-associated factor 3 (TRAF3) (a tumour suppressor gene implicated in innate and acquired anti-viral responses, already described in nasopharyngeal carcinoma), amplification of E2F1, and an aberrant activation of NF-KB and cell cycle. Moreover, a 3q amplicon expression was found and included transcription factors such as TP63, SOX2 and the oncogene PIK3CA, which are also Figure 3 . High risk HPV E6 and E7 oncoproteins and their role in cell cycle activation and loss of p53 tumor suppressor. HPV infection leads to deregulation of the cell cycle and loss of p53 tumours suppressor. E7 HPV protein binds to pRb and promotes its degradation resulting in the release and activation of the E2F transcription, inducing an increase of cyclin-dependent kinase inhibitor p16 INK4A and a re-entry into Sphase cell cycle. E6 HPV protein prevents the induction of apoptosis in response to the unscheduled S-phase entry through ubiquitination and proteosomal degradation of p53. p53 in normal conditions, induce p21 expression that inhibits cyclin-CDK complex and arrest cell cycle.
implicated in the homeostasis of epithelial stem cells and differentiation and frequent deletions of 11q are shown containing the ATM gene [46] .
Significant activating mutations of PIK3CA such as C > T mutations (E542K and E545K amino acid substitutions), have been described in HPV-related tumours [46] . These mutations are described to be related to a high activity of the apoliprotein B mRNA editing enzyme catalytic polypeptide-like (APOBEC) that generates a mutation signature in virally transformed cancers [47] . Inhibition of PI3K/AKT/mTOR pathway may be thus an interesting target for these patients as it plays a key role in cellular metabolism, proliferation and survival. Multiple inhibitors targeting PI3K (BKM120, XL147) or PI3K-mTOR (BEZ235, XL765, GSK1059615) are currently under investigation [48] . Surprisingly, results from the Beril-1, a phase II clinical trial with buparlisib (BKM120: a pan-PI3K inhibitor) and paclitaxel had shown worse PFS in HPV-related HNSCC patients than non HPV-related ones [49] . On the other hand, the PI3K pathway activation has been proposed as one of the resistance mechanisms of EGFR inhibitors in preclinical studies, suggesting that PI3K/mTOR inhibitors may be developed in patients who are EGFR inhibitor-resistant in addition to patients with the PIK3CA mutations [50] . However, in a recent article studying cetuximab (anti-EGFR antibody) with or without PX-866 (PI3K inhibitor), no association between HPV status and response to treatment was found [51] .
Targeting tyrosine kinase receptors may also be a potential therapeutic tool against HPV-related OPSCC. Fibroblast growth factor (FGF) pathway has been described as new likely therapeutic target in HPV-related OPSCC, with novel agents in active development [52] . Seiwert et al. demonstrated a prevalence of 17.6% of FGFR2 and FGFR3 somatic mutations among HPVrelated tumours, importantly the FGFR3 S249C was recurrently identified (previously reported in the TGCA study) [53] .
Generally, the lack of EGFR aberrations in HPV-related OPSCC is consistent in previous literature. EGFR alterations are inversely correlated with HPV status with absent levels of EGFR protein expression or gen amplification among HPV-related HNSCC [46, 54] . However, a subset of HPV-related OPSCC expresses high EGFR levels and is associated with worse outcomes [55] . Anti-EGFR therapy is widely being used in de-escalation clinical trials, relevant data about EGFR inhibition will be reported in the following years.
Immune system in HPV-related OPSCC and potential therapeutic targets A potential explanation for the survival benefit of HPV-related OPSCC patients may be due to tumour-infiltrating lymphocytes (TILs) conferring a protective effect through an adaptive host immune response directed against viral antigens [56] . HPV16 E7-specific T cells have been reported in OPSCC [57, 58] . In a study including 270 OPSCC patients, those expressing high versus low levels of TILs classified HPV-related patients into HR and lowrisk groups: 96% 3-year-survival in HPV-related-high-TILs; and 59% in HPV-related-low-TILs [59] . These data have been also confirmed in two further studies [60, 61] .
High expression of immune checkpoint receptors as programmed cell death-1 (PD-1) and its ligand (PD-L1), in intratumoural regulatory T cells have been described in HNSCC patients [62] . These findings support the role of PD-1 : PD-L1 interaction creating an 'immune-privileged site', finding around 70% of PD-L1 expression among HPV-related OPSCC examined [63] [64] [65] . Furthermore, recent results have suggested a model, in which TILs present in HPV-positive OPSCC, secrete INF-gamma and promote PD-L1 expression [66] .
Clinical trials of immunotherapeutic agents in HNSCC are currently being conducted studying HPV-related OPSCC as a sub-group. Pembrolizumab (anti-PD1) has shown a response rate of 20% in relapsed/refractory HNSCC [67] , and a recently new phase III clinical trial with nivolumab (anti-PD1) has demonstrated a significant improvement in survival in patients with HNSCC progressing after cisplatin (1-year survival rate 36% versus 16.6%), observing preliminary evidence that patients with p16
INK4a positive tumours may have a greater magnitude of nivolumab effect, independent of level of PD1 expression [68] .
Furthermore, bacterial/virus vaccines can deliver tumour antigens acting as an immune adjuvant due to immune system responses to a perceived infection [69] . Several such vaccines against E7, E6/E7 or even E2-expressing are now under investigation [70] [71] [72] . Adoptive T-cell transfer: T cells removed from a patient, genetically modified or treated to enhance their activity and reintroduced into the patient again, are also ongoing in a phase II trial on TILs for HPV-related cancers including HNSCC (NCT01585428) [69] .
Clinical and histopathological differences between HPV-related and non-HPV-related OPSCC HPV status has widely been described as an independent predictor of improved overall and disease-free survival (OS and DFS) in OPSCC patients [73] . One of the first studies to demonstrate these improved outcomes was conducted by Gillison et al. A 74% reduction in risk of death from cancer among patients with HPV-related OPSCC was found compared with those with non HPV-related OPSCC (HR: 0.26; 95% CI 0.07-0.98) [74] . A meta-analysis confirmed the data showing that patients with HPV-related OPSCC have a 28% reduce risk of death (meta HR: 0.72, 95% CI: 0.5-1) compared with non HPV-related OPSCC [75] .
Several phase II and III clinical trials in locally advanced HNSCC have also shown a survival benefit for patients with HPV-related cancers. Results from phase III clinical trials are summarised in Table 1 . In addition, the RTOG 0129 study indicates that clinical factors, such as smoking history and stage, could also influence the prognosis of patients with HPV-related HNSCC [76] . The combination of HPV status, tobacco smoking (pack-year) and tumour stage has shown to classify patients as having a low, intermediate, or high risk of death: 3-year rates of OS were 93% (95% CI 88.3-97.7), 70.8% (95% CI 60.7-80.8) and 46.2% (95% CI 34.7-57.5), respectively [73] . Additional analyses have indicated that patients with p16
INK4a
-positive OPSCC with T4 or N2c-N3 disease have a high risk of disease progression, even if tobacco exposure is <10 pack-years [77] . It is estimated that around 20% of HPV-related OPSCC patients have bad prognosis and this population needs to be clearly identify.
New classifications were proposed for the 8th edition AJCC-TNM for HPV-related OPSCC, some of them including nonanatomic factor such as tobacco use [78] [79] [80] . Finally, a new TNM staging system developed by O'Sullivan et al., with The International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S) and based on adjusted hazard ratios for the assessment of 1907 patients death risk, has been accepted for the 8th edition TNM for HPV-related OPSCC, resembling the N classification of nasopharyngeal carcinoma [81] (data are summarized in Table 2 ). It is interesting to note that HPV-related OPSCC patients were described as p16
INK4a -positive patients, and no other biomarkers were used for its classification.
HPV-related OPSCC are usually diagnosed in advanced stages, with low tumour size (T) and high nodal dissemination [82, 83] . From a histopathological perspective, HPV-related OPSCC are usually non-keratinizing, undifferentiated or basaloid squamous cell carcinomas [74, 82, 84] . These cancers also show less second primary neoplasms (SPN), probably due to less exposure to other risk factors such as tobacco use or alcohol consumption [85, 86] . Moreover, transcriptionally active HPV is absent in the mucosa surrounding HPV-related OPSCC; therefore, the absence of a cancerisation field effect is another explanation for the fact that these tumours develops less SPN and locoregional recurrences [87] . From a radiological point of view, they have well-defined borders, very frequently cystic nodal involvement and could have small or even occult primary tumours [88] . Main differences among HPVrelated and non-HPV OPSCC patients are summarised in Table 3 .
As described before, only a small proportion of OPSCC is attributed to other HR HPV types rather than 16 . A small retrospective study demonstrated that no significant survival differences were found among HPV16 and non-HPV16 OPSCC patients [89] . Nevertheless, few data are available about the outcomes of non-HPV16 related OPSCC and further studies are warranted.
Although the multimodal treatment of OPSCC makes it difficult to distinguish the effect of radiotherapy treatment from surgery or chemotherapy, clinical and pre-clinical studies support the evidence that HPV-related OPSCC are more radiosensitive than non-related ones [90, 91] . Radiosensitivity could be influenced by several factors associated with the molecular features of HPV-related tumours. Apoptosis signalling after radiation is higher in HPV-related OPSCC, probably due to the activation of a basal fraction of wild-type p53, which is not present in HPVnegative tumours showing p53 somatic mutations [91] . The inhibition of p53 and pRb due to the activity of E6 and E7 oncoproteins abrogates cell cycle check points, promotes fast progression through the S-phase and compromises the DNA repair ability in epithelial cells. As a result of the impaired activation of non-homologous end joining and homologous recombination DNA repair mechanisms, HPV-positive cells fail to resolve radiation-induced double strand breaks, increasing their intrinsic radiosensitivity [92, 93] . p16
INK4a impairs homologous recombination DNA repair through the downregulation of cyclin D1, and this could explain, at least in part, the prognostic and predictive value of p16
INK4a overexpression in OPSCC [94, 95] . Preclinical studies show that the use of PARP inhibitors could be a good strategy to increase the radiosensitivity in HPV-positive cells showing defective homologous recombination repair pathways [96] . HPV-related OPSCC radiosensitivity can be a Because 5-years OS was similar among N1, N2a and N2b, they re-termed the N categories. b Because 5-years OS was similar among T4a and T4b, they were no longer subdivided and it was re-termed as T4. HNSCC, head and neck squamous cell carcinoma; HPV, human papillomavirus; OS, overall survival; PFS, progression free survival.
influenced by additional molecular factors, such as the upregulation of base-excision or single-strand break DNA repair mechanisms or the lack of EGFR amplification [96, 97] . Differences in tumour microenvironment can also have an important impact on radiation response. In this sense, hypoxia signalling, which confer radioresistance in HPV non-related OPSCC, is lower in HPV-related ones [98] . Although the E6 and E7 activations are associated with the activation of mechanisms to evade the immune system response, immune infiltration is higher in HPV-positive than in HPV negative tumours and this could be associated with an increased radiotherapy response [99] .
HPV detection techniques
HPV testing is now mandatory for an accurate diagnosis and prognosis of patients with OPSCC [100] . There are several available techniques such as p16 INK4a IHC, detection of HPV-DNA by in situ hybridisation (ISH) or polymerase chain reaction (PCR), E6/E7 HPV-mRNA evaluation by ISH and reverse transcriptase-PCR (RT-PCR). Each technique yields different sensitivity and specificity profiles, but E6/E7 HPV-mRNA evaluation is considered the gold standard to confirm HPV causality since it detects oncogene transcriptional active HPVs. Comparison of main HPV detection techniques are summarised in Table 4 .
The p16 INK4a expression is a surrogate marker of HPV involvement and it is the most widely implemented technique in the clinical setting. In OPSCC, p16
INK4a shows a high sensitivity (!90%) and moderate (>80%) specificity compared with HPV16 E6-mRNA expression [101] . However, using p16 INK4a IHC alone is questionable, because a subset of HPV-DNA and mRNAnegative HNSCCs show diffuse p16
INK4a staining, indicating expression is not specific for HPV activity [102, 103] (e.g. a mutation on Rb can also overexpress p16
INK4a
) [46] . The discordant rates are around 25% of the cases [104] , being mostly p16
INK4a -positive and E6/E7 HPV mRNA-negative. In addition, there are substantial differences in how studies define p16
INK4a overexpression. In general, p16
INK4a staining has a high predictive value to identify HPV-related cancers when the pattern shows a strong and diffuse nuclear and cytoplasmic staining in at least 70% or more of the tumour [105] . It is important to remark that p16
INK4a detection outside of the oropharynx is an ineffective diagnostic tool, the assay has very poor positive predictive value in larynx and oral cavity carcinomas, indicating that p16
IHC should not be used as a surrogate biomarker of HPV outside the oropharynx [106, 107] .
In the previously mentioned study from our group, we estimated the odds ratios, sensitivity, specificity and area under the ROC curve for a battery of biomarkers related to HPV (p16 INK4a , pRb, CyD1 and p53), taking as gold standard HPV-DNA and E6*I mRNA positivity in OPSCC [7] . p16
INK4a was the marker that showed the most consistent association with the gold standard with a statistically significant higher area under the ROC curve; thus we concluded that using p16
INK4a and/or HPVmRNA in addition to HPV-DNA yielded the most accurate approximation to judge HPV carcinogenicity. A recently published meta-analysis shows that the combination of p16 INK4a IHC and HPV DNA detection is the method with the highest specificity to diagnose HPV-transformed OPSCC [108] . Interestingly, Rietbergen et al. [109] demonstrated that patients with p16
INK4a -positive but HPV-DNA-negative OPSCC showed a significantly less favourable survival than patients with p16
-positive and HPV-DNA-positive tumours (P < 0.001). This consideration should be taken into account for describing HPV-related OPSCC patients candidates for de-escalation treatment clinical trials, and be aware that p16
INK4a alone may not be the best biomarker to use.
Treatment implications: de-escalation strategies for locally advanced HPV-related OPSCC As described above, the proportion of HPV-related OPSCC has increased drastically in the last decade in some developed countries. Given that patients with HPV-related OPSCC have a younger median age, the morbidity associated with current treatments (xerostomia, necrosis, dysphagia, hypothyroidism, tracheotomies, dental and hearing problems) may have a large impact from the clinical, social and economic point of view [73, 110] . This, along with the fact that those patients show better prognosis, has resulted in the interest in establishing de-escalation trials seeking to maintain the OS while reducing acute and late toxicity derived from treatments.
Masterson et colleagues described four main de-escalation strategies carried out for patients with HPV-related OPSCC [111] .
1. Exploring cetuximab as an alternative to cisplatin when given concurrently with intensity-modulated radiation therapy (IMRT), attempting to reduce cisplatin late effects such as neuropathy, nephropathy and ototoxicity. 2. Reduction of radiation dose given in combination with chemotherapy as primary treatment (guided by induction chemotherapy response). Recently, results from the ECOG 1308 study have been published; induction chemotherapy was utilised for local-regionally advanced HPV-positive OPSCC to select responders for reduced dose radiotherapy to 54 Gy. Two-years PFS and OS of 80% and 94% were reported for patients with primary site complete response. Importantly, 2-years PFS was significantly higher among patients with 10 pack-years compared with those with >10 pack-years of smoking (92% versus 57%; P ¼ 0.014) [112] . 3. Reduced dose of IMRT with or without cisplatin in low-risk HPV-related OPSCC (Tobacco history <10 pack-year and clinical stage T1-T2, N1-N2b or T3, N0-N2b. 4. Reduction of adjuvant chemotherapy or radiotherapy dose following primary treatment with surgery (stratified on the basis of histopathology results).
Implementation of immunotherapy strategies in combination with IMRT are the next de-escalation studies being developed.
Nevertheless, HPV-positivity still remains a prognostic factor and no change management decisions on HPV-related OPSCC patients should be carried out except in the context of a clinical trial.
Preventative strategies
HPV immunisation targeting the L1 capsid proteins could be the most successful tool for primary prevention of HPV-related HNSCC. In controlled clinical trials, prophylactic HPV vaccines show 90%-100% efficacy in preventing vaccine-type HPV infections and associated anogenital precancerous lesions [113] , and have a great potential to reduce global anogenital cancer burden [114] . However, only one trial has shown reduction in prevalence of oral HPV-infection 4 years after the HPV vaccine compared with placebo [115] . Recently; Pinto et al. demonstrated that vaccination of males induce HPV antibodies levels at the oral cavity that correlate with circulating levels [116] . Moreover, HPV vaccination appears to provide protection against vaccine-type oral HPV infection among males and females in the general population [117] .
Regarding secondary prevention, some proposals have been described for a screening test. Transcervical ultrasonography is feasible to evaluate and visualise base of the tongue cancers [118] , playing a role in high risk individuals if otherwise identified; and HPV-DNA detection in oral rinses have the potential to derive into a screening tool, but very little data are available. Another potential tool for secondary prevention that has been postulated is HPV antibodies detection. HPV16 E6 seropositivity has been estimated to confer a 9-231 times increased risk for OPSCC [17, 84] . HPV16 E6 serology has been identified in two large studies as a promising predictive screening marker for OPSCC [119, 120] . In one of them, HPV16 E6 seropositivity was present in prediagnostic samples for 34.8% of patients with OPSCC and 0.6% of controls, yielding an OR as high as 274 (95% CI 110-681) [119] . However, these strong associations may not necessary translate into clinical utility, since the prevalence of OPSCC is still low and thus, even a specificity of a test over 99% may have a very low positive predictive value [121] . Moreover, there are not yet identifiable precancerous lesions of the oropharynx at which to intervene and no proven interventions even if precancerous lesions were identified. Then, there is not yet a validated preventive screening tool for general population and further investigation is warranted.
Regarding tertiary prevention, few data are available about HPV persistent infection after completing definitive therapy. In a preliminary study, oral HPV-DNA detection by oral rinses after 9, 12, 18 and 24 months post-treatment was evaluated [122] . Persistent HPV16 infection was associated with worse survival: 5 of the 6 patients with persistent HPV-DNA detection progressed in comparison to 9 of the 62 patients without persistent HPV-DNA detection. Further investigation on the role of persistent HPV infection used as a potential tertiary prevention tool is needed. However, one may take into account that operating characteristics, including low sensitivity (the prevalence of a positive oral rinse at diagnosis was only 54%), low confidence in the positive predictive value, and high number needed to treat, preclude immediate clinical adoption of the test [107] .
Discussion Conclusions
There has been a paradigmatic change in our understanding of HNSCC, in particular for oropharyngeal cancer that is witnessing the effects of a new and emerging risk factor such as oral HPV infection. The biology of HPV-related OPSCC is driven by E6 and E7 oncogenes that degrade p53 and pRb, respectively. Furthermore, recent activating mutations in PI3KCA and new immunotherapy strategies have been described.
Since the incidence of HPV-related OPSCCs is rapidly increasing, there is an urgent need to implement the most clinically valid HPV diagnostic assays to correctly classify true HPV-driven OPSCC and to rule out cancers with transient or oncogenic irrelevant HPV. This is important, in an era in which de-escalation treatments are available and can avoid late toxicity in those young patients with potential better prognosis.
It is also necessary to emphasise that the best strategy to fight against cancer is prevention, especially when the pathogenic agent is known and identifiable and the primary prevention tool such as HPV immunisation is available.
